Show simple item record

dc.contributor.authorLamorde, Mohammed
dc.contributor.authorByakika-Kibwika, Pauline
dc.contributor.authorMayito, Jonathan
dc.contributor.authorNabukeera, Lillian
dc.contributor.authorRyan, Mairin
dc.contributor.authorHanpithakpong, Warunee
dc.contributor.authorLefe`vree, Gilbert
dc.contributor.authorBackf, David J.
dc.contributor.authorKhoof, Saye H.
dc.contributor.authorMerry, Concepta
dc.date.accessioned2022-01-12T11:56:42Z
dc.date.available2022-01-12T11:56:42Z
dc.date.issued2013
dc.identifier.citationLamorde, M., Byakika-Kibwika, P., Mayito, J., Nabukeera, L., Ryan, M., Hanpithakpong, W., ... & Merry, C. (2013). Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment. Aids , 27 (6), 961-965. DOI:10.1097/QAD.0b013e32835cae3ben_US
dc.identifier.issn0269-9370
dc.identifier.other10.1097/QAD.0b013e32835cae3b
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/1224
dc.description.abstractMalaria and tuberculosis (TB) are co-endemic in many parts of the developing world. Although malaria transmission may occur throughout the duration of TB treatment, drug data between antimalarial drugs and anti- TB drugs are limited [1]. The WHO recommends artemisinin combination therapies (ACTs) for uncomplicated malaria caused by Plasmodium falciparum, whereas for TB treatment, the WHO recommends rifampicinbased therapy [2,3]. However, no data exist on drug interactions between ACTs and rifampicin-based TB treatment.en_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.subjectArtemether-lumefantrine combinationen_US
dc.subjectDrug interactionsen_US
dc.subjectRifampicinen_US
dc.titleLower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatmenten_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record